Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

Jan Neckář, Md Abdul Hye Khan, Garrett J. Gross, Michaela Cyprová, Jaroslav Hrdlička, Alena Kvasilová, J R Falck, William B. Campbell, Lenka Sedláková, Šárka Škutová, Veronika Olejníčková, Martina Gregorovičová, David Sedmera, František Kolář, John D. Imig

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Epoxyeicosatrienoic acids (EETs) and their synthetic analogs have cardiovascular protective effects. Here, we investigated the action of a novel EET analog EET-B on the progression of post-myocardial infarction (MI) heart failure in spontaneously hypertensive rats (SHR). Adult male SHR were divided into vehicle- and EET-B (10 mg/kg/day; p.o., 9 weeks)-treated groups. After 2 weeks of treatment, rats were subjected to 30-min left coronary artery occlusion or sham operation. Systolic blood pressure (SBP) and echocardiography (ECHO) measurements were performed at the beginning of study, 4 days before, and 7 weeks after MI. At the end of the study, tissue samples were collected for histological and biochemical analyses. We demonstrated that EET-B treatment did not affect blood pressure and cardiac parameters in SHR prior to MI. Fractional shortening (FS) was decreased to 18.4 + 1.0% in vehicle-treated MI rats compared with corresponding sham (30.6 + 1.0%) 7 weeks following MI induction. In infarcted SHR hearts, EET-B treatment improved FS (23.7 + 0.7%), markedly increased heme oxygenase-1 (HO-1) immunopositivity in cardiomyocytes and reduced cardiac inflammation and fibrosis (by 13 and 19%, respectively). In conclusion, these findings suggest that EET analog EET-B has beneficial therapeutic actions to reduce cardiac remodeling in SHR subjected to MI.

Original languageEnglish (US)
Pages (from-to)939-951
Number of pages13
JournalClinical science
Volume133
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Inbred SHR Rats
Myocardial Infarction
Acids
Blood Pressure
Heme Oxygenase-1
Coronary Occlusion
Cardiac Myocytes
Echocardiography
Coronary Vessels
Fibrosis
Heart Failure
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neckář, J., Abdul Hye Khan, M., Gross, G. J., Cyprová, M., Hrdlička, J., Kvasilová, A., ... Imig, J. D. (2019). Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clinical science, 133(8), 939-951. https://doi.org/10.1042/CS20180728

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. / Neckář, Jan; Abdul Hye Khan, Md; Gross, Garrett J.; Cyprová, Michaela; Hrdlička, Jaroslav; Kvasilová, Alena; Falck, J R; Campbell, William B.; Sedláková, Lenka; Škutová, Šárka; Olejníčková, Veronika; Gregorovičová, Martina; Sedmera, David; Kolář, František; Imig, John D.

In: Clinical science, Vol. 133, No. 8, 01.01.2019, p. 939-951.

Research output: Contribution to journalArticle

Neckář, J, Abdul Hye Khan, M, Gross, GJ, Cyprová, M, Hrdlička, J, Kvasilová, A, Falck, JR, Campbell, WB, Sedláková, L, Škutová, Š, Olejníčková, V, Gregorovičová, M, Sedmera, D, Kolář, F & Imig, JD 2019, 'Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats', Clinical science, vol. 133, no. 8, pp. 939-951. https://doi.org/10.1042/CS20180728
Neckář J, Abdul Hye Khan M, Gross GJ, Cyprová M, Hrdlička J, Kvasilová A et al. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clinical science. 2019 Jan 1;133(8):939-951. https://doi.org/10.1042/CS20180728
Neckář, Jan ; Abdul Hye Khan, Md ; Gross, Garrett J. ; Cyprová, Michaela ; Hrdlička, Jaroslav ; Kvasilová, Alena ; Falck, J R ; Campbell, William B. ; Sedláková, Lenka ; Škutová, Šárka ; Olejníčková, Veronika ; Gregorovičová, Martina ; Sedmera, David ; Kolář, František ; Imig, John D. / Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. In: Clinical science. 2019 ; Vol. 133, No. 8. pp. 939-951.
@article{1a968b4d609c4a179bcf11350e86c036,
title = "Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats",
abstract = "Epoxyeicosatrienoic acids (EETs) and their synthetic analogs have cardiovascular protective effects. Here, we investigated the action of a novel EET analog EET-B on the progression of post-myocardial infarction (MI) heart failure in spontaneously hypertensive rats (SHR). Adult male SHR were divided into vehicle- and EET-B (10 mg/kg/day; p.o., 9 weeks)-treated groups. After 2 weeks of treatment, rats were subjected to 30-min left coronary artery occlusion or sham operation. Systolic blood pressure (SBP) and echocardiography (ECHO) measurements were performed at the beginning of study, 4 days before, and 7 weeks after MI. At the end of the study, tissue samples were collected for histological and biochemical analyses. We demonstrated that EET-B treatment did not affect blood pressure and cardiac parameters in SHR prior to MI. Fractional shortening (FS) was decreased to 18.4 + − 1.0{\%} in vehicle-treated MI rats compared with corresponding sham (30.6 + − 1.0{\%}) 7 weeks following MI induction. In infarcted SHR hearts, EET-B treatment improved FS (23.7 + − 0.7{\%}), markedly increased heme oxygenase-1 (HO-1) immunopositivity in cardiomyocytes and reduced cardiac inflammation and fibrosis (by 13 and 19{\%}, respectively). In conclusion, these findings suggest that EET analog EET-B has beneficial therapeutic actions to reduce cardiac remodeling in SHR subjected to MI.",
author = "Jan Neck{\'a}ř and {Abdul Hye Khan}, Md and Gross, {Garrett J.} and Michaela Cyprov{\'a} and Jaroslav Hrdlička and Alena Kvasilov{\'a} and Falck, {J R} and Campbell, {William B.} and Lenka Sedl{\'a}kov{\'a} and Š{\'a}rka Škutov{\'a} and Veronika Olejn{\'i}čkov{\'a} and Martina Gregorovičov{\'a} and David Sedmera and František Kol{\'a}ř and Imig, {John D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1042/CS20180728",
language = "English (US)",
volume = "133",
pages = "939--951",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "8",

}

TY - JOUR

T1 - Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

AU - Neckář, Jan

AU - Abdul Hye Khan, Md

AU - Gross, Garrett J.

AU - Cyprová, Michaela

AU - Hrdlička, Jaroslav

AU - Kvasilová, Alena

AU - Falck, J R

AU - Campbell, William B.

AU - Sedláková, Lenka

AU - Škutová, Šárka

AU - Olejníčková, Veronika

AU - Gregorovičová, Martina

AU - Sedmera, David

AU - Kolář, František

AU - Imig, John D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Epoxyeicosatrienoic acids (EETs) and their synthetic analogs have cardiovascular protective effects. Here, we investigated the action of a novel EET analog EET-B on the progression of post-myocardial infarction (MI) heart failure in spontaneously hypertensive rats (SHR). Adult male SHR were divided into vehicle- and EET-B (10 mg/kg/day; p.o., 9 weeks)-treated groups. After 2 weeks of treatment, rats were subjected to 30-min left coronary artery occlusion or sham operation. Systolic blood pressure (SBP) and echocardiography (ECHO) measurements were performed at the beginning of study, 4 days before, and 7 weeks after MI. At the end of the study, tissue samples were collected for histological and biochemical analyses. We demonstrated that EET-B treatment did not affect blood pressure and cardiac parameters in SHR prior to MI. Fractional shortening (FS) was decreased to 18.4 + − 1.0% in vehicle-treated MI rats compared with corresponding sham (30.6 + − 1.0%) 7 weeks following MI induction. In infarcted SHR hearts, EET-B treatment improved FS (23.7 + − 0.7%), markedly increased heme oxygenase-1 (HO-1) immunopositivity in cardiomyocytes and reduced cardiac inflammation and fibrosis (by 13 and 19%, respectively). In conclusion, these findings suggest that EET analog EET-B has beneficial therapeutic actions to reduce cardiac remodeling in SHR subjected to MI.

AB - Epoxyeicosatrienoic acids (EETs) and their synthetic analogs have cardiovascular protective effects. Here, we investigated the action of a novel EET analog EET-B on the progression of post-myocardial infarction (MI) heart failure in spontaneously hypertensive rats (SHR). Adult male SHR were divided into vehicle- and EET-B (10 mg/kg/day; p.o., 9 weeks)-treated groups. After 2 weeks of treatment, rats were subjected to 30-min left coronary artery occlusion or sham operation. Systolic blood pressure (SBP) and echocardiography (ECHO) measurements were performed at the beginning of study, 4 days before, and 7 weeks after MI. At the end of the study, tissue samples were collected for histological and biochemical analyses. We demonstrated that EET-B treatment did not affect blood pressure and cardiac parameters in SHR prior to MI. Fractional shortening (FS) was decreased to 18.4 + − 1.0% in vehicle-treated MI rats compared with corresponding sham (30.6 + − 1.0%) 7 weeks following MI induction. In infarcted SHR hearts, EET-B treatment improved FS (23.7 + − 0.7%), markedly increased heme oxygenase-1 (HO-1) immunopositivity in cardiomyocytes and reduced cardiac inflammation and fibrosis (by 13 and 19%, respectively). In conclusion, these findings suggest that EET analog EET-B has beneficial therapeutic actions to reduce cardiac remodeling in SHR subjected to MI.

UR - http://www.scopus.com/inward/record.url?scp=85064975365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064975365&partnerID=8YFLogxK

U2 - 10.1042/CS20180728

DO - 10.1042/CS20180728

M3 - Article

C2 - 30979784

AN - SCOPUS:85064975365

VL - 133

SP - 939

EP - 951

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 8

ER -